

Russell William Jenkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/531254/publications.pdf>

Version: 2024-02-01

23
papers

5,444
citations

394421

19
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

11016
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutant IDH Inhibits IFN β 's TET2 Signaling to Promote Immune Evasion and Tumor Maintenance in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 812-835.	9.4	55
2	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.7	193
3	Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	35
4	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. <i>Communications Biology</i> , 2021, 4, 122.	4.4	139
5	861'...Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy. , 2021, 9, A902-A902.		1
6	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. <i>Cancers</i> , 2021, 13, 6052.	3.7	15
7	Targeting TANK-binding kinase 1 (TBK1) in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1065-1078.	3.4	26
8	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	6.7	83
9	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018, 118, 9-16.	6.4	944
10	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	9.4	392
11	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	12.2	38
12	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	9.4	503
13	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	28.9	892
14	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
15	3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. <i>Lab on A Chip</i> , 2018, 18, 3129-3143.	6.0	185
16	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4854-4864.	7.0	49
17	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018, 24, 1143-1150.	30.7	212
18	Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. <i>Cell Systems</i> , 2017, 5, 105-118.e9.	6.2	40

#	ARTICLE	IF	CITATIONS
19	Refining Targeted Therapy Opportunities for <i>BRAF</i> -Mutant Melanoma. <i>Cancer Discovery</i> , 2017, 7, 799-801.	9.4	4
20	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. <i>Cancer Immunology Research</i> , 2016, 4, 520-530.	3.4	79
21	<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma management. <i>Melanoma Management</i> , 2016, 3, 47-59.	0.5	12
22	Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. <i>Clinical Lung Cancer</i> , 2015, 16, e101-e104.	2.6	85
23	Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2013, 88, E265-72.	4.1	19